Charles Schwab Investment Management Inc. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 387,187 shares of the company’s stock after purchasing an additional 20,346 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Kymera Therapeutics were worth $15,577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of KYMR. Blue Trust Inc. grew its holdings in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares during the period. Quarry LP bought a new stake in shares of Kymera Therapeutics in the third quarter worth $95,000. Thrivent Financial for Lutherans bought a new stake in shares of Kymera Therapeutics in the third quarter worth $313,000. Finally, Walleye Capital LLC bought a new stake in shares of Kymera Therapeutics in the third quarter worth $472,000.

Insider Transactions at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now owns 54,826 shares in the company, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on KYMR. BMO Capital Markets began coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company. Citigroup assumed coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $52.00 price target for the company. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd. BTIG Research assumed coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target for the company. Finally, HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Kymera Therapeutics Stock Performance

KYMR stock opened at $33.21 on Friday. Kymera Therapeutics, Inc. has a one year low of $29.07 and a one year high of $53.27. The company’s fifty day moving average price is $36.90 and its 200-day moving average price is $42.44. The company has a market capitalization of $2.16 billion, a PE ratio of -14.19 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.